TG Therapeutics is entering 2025 with investors accustomed to a beat-and-raise guidance policy and the company needs to deliver. Learn more on TGTX stock here.

The bulls believed these drone-like eVTOL aircraft would replace traditional helicopters because they were cheaper, greener, ...

Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.

The deal marks The Exigent Group's second acquisition in Northwest Ohio, following its partnership with Smith-Boughan ...

Eight manufacturers are putting what they learned during the Residential Cold Climate Heat Pump Technology Challenge into new ...

Insider activity is seldom enough to move a market independently but can signal how a company’s management thinks. Those ...